Novartis To Re-file Acute Heart Failure Drug Serelaxin As EU Denies Approval RTT News Swiss drug maker Novartis AG (NVS: Quote) Friday announced that it will shortly submit a revised filing package, including new data analyses, for re-examination for conditional marketing authorization of RLX030 or serelaxin for acute heart failure, as ... |
